Kala Pharmaceuticals Announces New Drug Application for INVELTYSTM (KPI-121 1%) Has Been Accepted for Review by the U.S. Food and Drug Administration

Kala Pharmaceuticals Announces Topline Results for Two Phase 3 Trials (STRIDE 1 and STRIDE 2) of KPI-121 0.25% in Dry Eye Disease

Zafgen Reports Strong Clinical Progress and Updates Outlook for 2018

Magenta Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9th, 2018

Constellation Pharmaceuticals to Present at 36th Annual JP Morgan Healthcare Conference

Rhythm Pharmaceuticals Announces Progress in Clinical Development of Setmelanotide for Treatment of Rare Genetic Disorders of Obesity

Editas Medicine to Present at the 36th Annual J.P. Morgan Healthcare Conference

Foundation Medicine to Present at the 36th Annual J.P. Morgan Healthcare Conference

GBT to Present at the 36th Annual J.P. Morgan Healthcare Conference

Jounce Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference

MyoKardia to Present at 36th Annual J.P. Morgan Healthcare Conference

Eleven Biotherapeutics to Present at Biotech Showcase 2018

Agios Submits New Drug Application to the FDA for Ivosidenib for the Treatment of Patients with Relapsed/Refractory AML and an IDH1 Mutation

GBT Appoints Wendy L. Yarno to Board of Directors

bluebird bio to Present at Investor Conferences in January

TARIS Biomedical® Announces $25M Series B Financing

TARIS and Bristol-Myers Squibb Announce Clinical Trial Collaboration

CytomX Therapeutics Added to NASDAQ Biotechnology Index

Global Blood Therapeutics Prices a $100.0 Million Common Stock Public Offering

Allena Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update

Jounce Therapeutics Added to NASDAQ Biotechnology Index

Relay Therapeutics Secures $63 Million in Series B Financing

Eleven Biotherapeutics Announces Chief Scientific Officer To Chair A Session At The Antibody Engineering And Therapeutics Meeting

Neon Therapeutics Expands Board of Directors with Leading Experts in Cancer Drug Discovery and Corporate Finance

Constellation Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 PROSTAR Combination Study of CPI-1205 in Advanced Form of Prostate Cancer

bluebird bio Announces Pricing of Public Offering of Common Stock

Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock

Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock

New Data from Ivosidenib Phase 1 Dose-Escalation and Expansion Trial Demonstrate Durable Responses in Patients with IDH1m Relapsed or Refractory AML

Data from Phase 1 Studies of Ivosidenib or Enasidenib in Combination with Full Doses of Standard of Care Chemotherapy Demonstrate Tolerability and Preliminary Clinical Activity in Newly Diagnosed AML Patients With an IDH Mutation

bluebird bio Presents Updated Data from HGB-205 Study of LentiGlobinTM Gene Therapy in Patients with Severe Sickle Cell Disease and Transfusion-Dependent β-Thalassemia at American Society of Hematology Annual Meeting

Editas Medicine Reports Data Supporting Multiple Approaches to Create Treatments for Sickle Cell Disease and Beta-Thalassemia

GBT Announces Presentation of Six Studies at ASH Supporting Voxelotor Sickle Cell Disease (SCD) Program

Magenta Therapeutics Presents Preclinical Data from Stem Cell Mobilization and Expansion Programs

Magenta Therapeutics’ Expanded Stem Cell Product, MGTA-456, Engrafts in 100% of Patients, Leading to Robust Neutrophil and Immune Recovery in Two Phase 2 Clinical Studies

Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting

bluebird bio Announces Updated Clinical Results from Ongoing Phase 1 Multicenter Study of LentiGlobinâ„¢ Gene Therapy in Severe Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

bluebird bio Presents New Data from Clinical Studies of LentiGlobinTM Gene Therapy in Transfusion-Dependent β-Thalassemia at American Society of Hematology Annual Meeting

Agios Presents Updated Data from DRIVE PK Study Demonstrating AG-348 is Well-Tolerated and Results in Clinically Relevant, Rapid and Sustained Hemoglobin Increases in Patients with Pyruvate Kinase Deficiency

Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of Avapritinib (BLU-285) in Patients with Advanced Systemic Mastocytosis Showing Evidence of Strong Clinical Activity

GBT Announces New Phase 2a Data at ASH for Voxelotor in Adolescents with Sickle Cell Disease (SCD)

Magenta Therapeutics’ Lead Targeted Antibody Drug Conjugate Shows Promising Preclinical Results for Non-Genotoxic Conditioning for Bone Marrow Transplant

bluebird bio and TC BioPharm Announce Strategic Collaboration to Research and Develop Gamma Delta CAR T Cell Product Candidates for Cancer Immunotherapy

Jounce Therapeutics to Present at BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference

New Data Published in Journal Cell Show Robust Mobilization of Highly Engraftable Stem Cells in Mouse Models with Combination of GROβ and Plerixafor

Neon Therapeutics Announces Clinical Trial Collaboration with Merck

Sage Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference

Sage Therapeutics Reports Positive Top-line Results from Phase 2 Placebo-Controlled Trial of SAGE-217 in Major Depressive Disorder

Editas Medicine, Inc., Announces Pricing of $50 Million Offering of Common Stock

Foundation Medicine and Collaborators to Present New Data at the American Society of Hematology (ASH) Annual Meeting that Supports Use of FoundationOne®Heme to Advance Personalized Medicine in Blood Cancers